Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine-Reference-Cited by-同舟云学术

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Published:2014-07 Issue:7 Volume:38 Page:751-755
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Bally Cecile,Adès Lionel,Renneville Aline,Sebert Marie,Eclache Virginie,Preudhomme Claude,Mozziconacci Marie-Joelle,de The Hugues,Lehmann-Che Jacqueline,Fenaux Pierre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes;Shen;J Clin Oncol,2010

3. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine;Itzykson;Leukemia,2011

4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine;Itzykson;Blood,2011

5. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience;Lamarque;Blood,2012

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment;Laboratory Medicine;2024-07-13

2. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes;International Journal of Molecular Sciences;2024-04-23

3. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms;Blood Cancer Journal;2024-04-09

4. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis;Cancers;2024-03-29

5. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies;Frontiers in Immunology;2024-02-23